Roche Holding AG (RHHBY)
| Market Cap | 344.27B +18.1% |
| Revenue (ttm) | 77.92B -0.8% |
| Net Income | 15.27B +30.9% |
| EPS | 18.98 +30.6% |
| Shares Out | n/a |
| PE Ratio | 22.54 |
| Forward PE | 16.98 |
| Dividend | 0.97 (1.80%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 1,217,386 |
| Open | 53.83 |
| Previous Close | 53.37 |
| Day's Range | 53.66 - 54.18 |
| 52-Week Range | 40.07 - 60.85 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 60.30 (+11.48%) |
| Earnings Date | Oct 22, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price target is $60.3, which is an increase of 11.48% from the latest price.
News
Roche's Vamikibart Shows Promise in Vision Treatment, RHHBY Dividend Remains Attractive
Roche's Vamikibart Shows Promise in Vision Treatment, RHHBY Dividend Remains Attractive
Roche's Vamikibart Shows One-Year Vision Benefits In Uveitic Macular Edema; FDA Accepts Filing
(RTTNews) - Roche (RHHBY, RO.SW, ROG.SW) announced positive one-year results from its Phase III MEERKAT and SANDCAT studies evaluating investigational therapy vamikibart in adults with uveitic macular...
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT s...
Genentech announces FDA approval of Tecentriq combination
Genentech, a member of Roche (RHHBY), announced that the FDA has approved Tecentriq and Tecentriq Hybreza in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III...
FDA Approves Roche's Tecentriq-Based Regimens For Stage 3 Colon Cancer
(RTTNews) - Roche (RHHBY) said Friday that the U.S. FDA approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), in combination with chemotherapy, for the adjuvan...
FDA Approves Genentech's Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has appro...
FDA approves Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
Basel, 9 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab an...
FDA Approves Roche's Tecentriq for Stage III dMMR Colon Cancer, Boosting RHHBY's Growth Prospects
FDA Approves Roche's Tecentriq for Stage III dMMR Colon Cancer, Boosting RHHBY's Growth Prospects
Roche (RHHBY) Partners with Defand Therapeutics in $1 Billion Oncology Collaboration
Roche (RHHBY) Partners with Defand Therapeutics in $1 Billion Oncology Collaboration
Zealand, Roche's obesity drug helps patients lose up to 9.2% weight in mid-stage trial
Zealand Pharma said on Wednesday its experimental drug helped people who are overweight or obese and have type 2 diabetes lose up to 9.2% of their body weight in a mid-stage trial. The Danish compan...
Roche Boosts Ebola Testing In Congo Region With Molecular Equipment As Outbreak Spreads
(RTTNews) - On Wednesday, Roche's (RHHBY) diagnostic division, Roche Diagnostics has provided two molecular testing instruments to the Institut National de Sante Publique (INSP) to strengthen laborato...
Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC
Roche Diagnostics has provided two molecular testing instruments to Institut National de Santé Publique (INSP) to support Ebola testing capacity in the DRC. Roche will preconfigure the instruments and...
Roche Stocks: Genentech Commits $100 Million Upfront in Potential $1.27 Billion Parkinson's Deal
Roche Stocks: Genentech Commits $100 Million Upfront in Potential $1.27 Billion Parkinson's Deal
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical development, launch readiness, commercialization and global medical strategy Appointment strengthens commerc...
Alector price target raised to $3 from $2 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Alector (ALEC) to $3 from $2 and keeps an Underweight rating on the shares after the company announced that Genentech (RHHBY) has…
Why is Alector Stock (ALEC) 60% Higher Today?
Shares in U.S. biotech firm Alector ($ALEC) surged 60% in pre-market trading today after Swiss drugmaker Roche ($RHHBY) agreed to pay up to $1.27 billion. to license its experimental treatment…
Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental treatment for Parkinson's disease, the US biotech said on Monday, sending its shares surging 72% in premarket tra...
Alector enters exclusive AL050 global licensing agreement with Genentech
Alector (ALEC) announced it has entered into an exclusive global licensing agreement with Genentech, a member of Roche (RHHBY), granting Genentech worldwide rights to develop and commercialize Alector...
Roche Stocks Rises as Autonomous Labs Move AI Into Wet Research
Roche Stocks Rises as Autonomous Labs Move AI Into Wet Research
Roche’s Genentech reports new data from Voyager study of Vabysmo
Genentech, a member of the Roche (RHHBY) Group, announced new data from the Voyager study evaluating the effectiveness, durability and safety of Vabysmo in wet age-related macular degeneration, diabet...
Roche’s Genentech reports detailed results from evERA Breast Cancer study
Genentech, a member of the Roche (RHHBY) Group, announced that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with everolimus significantly im...
Genentech's Giredestrant Posts Positive Phase 3 Data Ahead Of November, December FDA Dates
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that detailed Phase 3 evERA study results published in the New England Journal of Medicine showed that giredestrant combined with ...
Roche Highlights Real-World Vabysmo Performance Across Major Retinal Diseases At EURETINA
(RTTNews) - Roche (RHHBY) announced new data from the VOYAGER study showing that Vabysmo (faricimab) continued to demonstrate effectiveness, durability and safety in real-world clinical practice acros...
Roche Says Giredestrant- Everolimus Combo Significantly Improves PFS In ER+ Breast Cancer
(RTTNews) - Swiss drug major Roche Holding AG (RHHBY, RO.SW, ROG.SW) announced Thursday that giredestrant combination significantly improved progression-free survival in ER-positive advanced breast ca...
Roche's Vabysmo Shows Real-World Effectiveness Across Retinal Diseases
(RTTNews) - Thursday, Roche (RHHBY) reported new data from the VOYAGER study showing that Vabysmo (faricimab) delivered durable effectiveness and a consistent safety profile in patients with wet age-r...